Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Lunit Announces Collaboration with AstraZeneca to Develop AI-Powered Digital Pathology Risk Assessment Tools for NSCLC 2024-11-18 22:00
Lunit Partners with VIDI Group to Deliver AI-Powered Mammography to France's Largest Radiology Network 2024-11-13 22:00
Lunit Shows Promise of AI in Predicting Immunotherapy Response for Rare Cancer Patients at SITC 2024 2024-11-08 22:00
Lunit AI Predicts Breast Cancer Risk Up to 6 Years in Advance 2024-10-23 21:00
Lunit to Present AI-Analyzed Immune Phenotype Study as Immunotherapy Response Predictor for Advanced Gastric Cancer at ESMO Congress 2024 2024-09-10 21:00
Lunit Joins Roche's Digital Pathology Open Environment to Advance Cancer Biomarker Testing 2024-09-09 21:00
Immune Phenotyping Identified as Promising Predictive Biomarker by Lunit AI in Biliary Tract Cancer - New publication in CCR 2024-09-03 21:00
Lunit's AI for Tuberculosis Detection Tops in 12-Product Comparative Study 2024-08-06 21:00
Lunit's AI Solution Enhances Qatar's National Breast Cancer Screening Program 2024-07-22 21:00
Lunit to Showcase 7 Studies at ASCO 2024, including AI Innovations in HER2 Quantification, and Multimodal Predictive Models for Immunotherapy Response 2024-05-24 22:07
Lunit Completes Acquisition of Volpara: Pioneering Next-Level of AI-Driven Cancer Care 2024-05-22 21:00
Lunit Achieves Historic Milestone: 100 Peer-Reviewed Papers Published on Its AI Medical Imaging Suite 2024-05-20 21:00
Lunit's AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals 2024-04-08 21:00
Lunit to Showcase 7 Studies at AACR 2024: Unveiling AI Innovations in HER2 Expression-Mutation Analysis and CNTN4 Biomarker Identification 2024-04-01 21:00
Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients 2024-03-26 21:00
Lunit Expands Presence in Europe: to Deliver AI-powered Cancer Screening Solution to France and Portugal 2024-03-18 21:00
Lunit SCOPE AI Enhances Pathologist Concordance and Accuracy in HER2, ER, and PR Assessment - New Study in Breast Cancer Research 2024-03-14 21:00
Update on Lunit's Acquisition of Volpara: New Zealand High Court Initial Approval Secured 2024-03-13 21:00
Lunit Presents Seven Study Results at ECR 2024: Showcasing AI's Robust Performance in Diverse Clinical Settings 2024-02-28 22:03
New Study Demonstrates Predictive Value of Lunit SCOPE IO to Predict Outcomes of Immune Checkpoint Inhibitor Therapy Across Diverse Tumors - published in the JITC 2024-02-16 22:03
1 2 3 4